Wegovy (semaglutide) lists at $1,349 per month — but most people who get it pay far less. SunnyPharma’s cost-transparency mission is to show you exactly what you’ll pay based on your coverage situation, so you can find the most affordable legitimate path to treatment.
What you pay for Wegovy depends almost entirely on your insurance status. With commercial insurance and a savings card: as little as $25/month. Without insurance via NovoCare direct: $199–$499/month. Medicare Part D members with obesity: $50/month starting July 1, 2026 through the Medicare GLP-1 Bridge. Uninsured with low income: potentially free through Novo Nordisk’s Patient Assistance Program.
Key Takeaways
- The $1,349 list price is what almost no one pays — your actual cost depends on your insurance situation.
- Medicare Part D members with obesity can access Wegovy for $50/month starting July 1, 2026 through the Medicare GLP-1 Bridge program.
- NovoCare direct (Novo Nordisk’s own pharmacy) is the cheapest brand-name option for uninsured patients — $199–$499/month depending on dose, with no GoodRx stacking needed or possible.
- The oral Wegovy pill ($149–$299/month) is now FDA-approved and available, offering a lower entry price than the injection at starter doses.
- Compounded semaglutide is legal via 503A pharmacies with a personalized prescription but is not FDA-approved and is not the same as branded Wegovy.
Wegovy Cost Without Insurance
Without insurance, you have three distinct cash-pay channels for Wegovy. The price gap between them is large — up to $1,150/month for the same medication.
| Channel | Monthly Cost | Notes |
|---|---|---|
| NovoCare Pharmacy (direct) | $199–$499 | Novo Nordisk’s own mail-order pharmacy. Cheapest brand-name option. Requires valid prescription. All doses. Home delivery. novocare.com |
| Oral Wegovy pill (self-pay) | $149–$299 | FDA-approved Dec 2025. Starter dose (1.5 mg) $149/month via NovoCare. Daily pill, no refrigeration required. Higher doses cost more. |
| Retail pharmacy (GoodRx coupon) | $1,229–$1,419 | GoodRx reduces retail price ~10%. Cheapest retail option: Costco $1,229–$1,295. Cannot stack GoodRx with NovoCare direct program. |
| Compounded semaglutide (telehealth) | $99–$400 | Legal via 503A compounding pharmacies when prescriber identifies personalization need. Not FDA-approved. Not interchangeable with branded Wegovy. See section below. |
Important: GoodRx coupons and NovoCare direct pricing cannot be combined. NovoCare direct is typically $730–$1,050 cheaper per month than GoodRx retail for the same dose — for most uninsured patients, NovoCare direct is the better option unless you need same-day local pickup.
Wegovy Cost With Insurance
Commercial insurance coverage for Wegovy varies widely. Coverage decisions shift frequently — GoodRx research found that over 12 million people lost commercial coverage for Wegovy in 2026 alone.[1]
If your plan covers Wegovy, you can add the Wegovy Savings Offer (NovoCare copay card) to bring your cost as low as $25/month — subject to a $100/month maximum savings cap, commercial insurance only, government insurance excluded.[2] The card covers both the injection and oral pill.
If your plan covers Wegovy but requires prior authorization (PA), your doctor submits the PA request. Denial rates are high but over 65% of appeals succeed, according to patient advocacy data. While appealing, you can bridge with the NovoCare self-pay option or the oral pill.
If your plan does not cover Wegovy at all, the NovoCare Savings Offer does not apply — it works on top of insurance copays, not in place of insurance. Your best option is NovoCare direct self-pay.
Wegovy Cost on Medicare — The $50/Month Bridge
Medicare historically could not cover drugs prescribed solely for weight loss — a statutory prohibition in place since Part D was created in 2006. That changes on July 1, 2026.
The Medicare GLP-1 Bridge, announced by CMS in May 2026, provides eligible Medicare Part D members access to Wegovy (injection and pill) and Zepbound KwikPen for a flat $50/month copayment — regardless of benefit phase. The program runs through December 31, 2027.[3]
You are eligible if you are enrolled in a Medicare Part D plan and your doctor prescribes Wegovy specifically for obesity (not for the cardiovascular or MASH indications, which have separate Part D coverage). The $50 copay does not count toward the annual Part D $2,100 out-of-pocket cap.
To access the Bridge: speak with your physician about eligibility, then check with your Part D plan. Part D sponsors do not need to opt in — the program is nationwide and applies automatically.
Medicare Advantage members with Part D drug coverage are also included. If you currently receive a GLP-1 for diabetes or cardiovascular disease through standard Part D, that coverage continues separately — the Bridge adds obesity coverage on top.
Wegovy Patient Assistance Program
Novo Nordisk operates a Patient Assistance Program (PAP) that may provide Wegovy at no cost or reduced cost to eligible patients. Eligibility is based on income and insurance status.[4]
To apply: visit NovoCare.com or call 1-888-693-4686. Your prescriber will need to participate in the application. Eligibility criteria change — confirm current income thresholds directly with Novo Nordisk at time of application.
- NeedyMeds (needymeds.org) — maintains an up-to-date database of manufacturer PAPs including Novo Nordisk’s
- RxAssist (rxassist.org) — independent PAP navigator with eligibility screening
- Patient Advocate Foundation — connects patients to TotalAssist fund for GLP-1 out-of-pocket costs
Wegovy Pill vs. Injection Cost
The oral Wegovy pill (semaglutide, once daily) received FDA approval in December 2025 and became available in January 2026.[5] Both the injection and pill contain semaglutide as the active ingredient. The differences that matter for cost planning:
| Wegovy Injection | Wegovy Pill | |
|---|---|---|
| List price | $1,349/month | $1,349/month |
| NovoCare self-pay | $199–$499/month | $149–$299/month |
| With commercial insurance + savings card | As low as $25/month | As low as $25/month |
| Medicare GLP-1 Bridge | $50/month (all doses) | $50/month (all doses) |
| Dosing frequency | Once weekly (subcutaneous) | Once daily (oral, 30-min pre-meal fast) |
| Refrigeration | Required | Not required |
| Starting dose | 0.25 mg injection | 1.5 mg tablet |
For self-pay patients, the oral pill’s lower entry price ($149/month vs. $199/month for the injection at the starter dose) makes it worth discussing with your prescriber as a cost-access strategy.
Compounded Semaglutide — What It Costs and What It Is
Compounded semaglutide is available from telehealth platforms for $99–$400/month in 2026. It became widely available during FDA-declared semaglutide shortages (2022–2025). The shortage is now resolved, but 503A compounding pharmacies may still prepare compounded semaglutide when a licensed prescriber determines a patient needs a personalized formulation — for example, a specific dose strength not available commercially, or a formulation combined with another ingredient such as B12.[6]
What compounded semaglutide is not: it is not FDA-approved, not the same pen device as Wegovy, and not covered under the Medicare GLP-1 Bridge or most insurance plans. The FDA has issued safety communications about dosing errors and sterility risks with compounded injectable semaglutide products.[6]
If you choose a compounded option, verify the pharmacy holds a state board of pharmacy license and is registered with the FDA as a 503A or 503B facility. The National Association of Boards of Pharmacy (nabp.pharmacy) maintains a searchable registry.
Frequently Asked Questions About Wegovy Cost
How much does Wegovy cost per month without insurance?
Without insurance, Wegovy costs $1,349/month at retail pharmacies, but most patients pay far less through direct channels. Novo Nordisk’s NovoCare Pharmacy offers Wegovy injections for $199–$499/month and the oral pill for $149–$299/month, depending on dose. Compounded semaglutide via telehealth platforms runs $99–$400/month and is legal under 503A pharmacy rules, though it is not FDA-approved. For most uninsured patients, NovoCare direct is the cheapest brand-name option — roughly $730 less per month than GoodRx retail pricing at Costco.
Does Medicare cover Wegovy for weight loss in 2026?
Yes — starting July 1, 2026. CMS announced the Medicare GLP-1 Bridge program in May 2026, which gives eligible Medicare Part D members access to Wegovy (injection and pill) for a flat $50/month copayment through December 31, 2027. You must have a prescription specifically for obesity treatment. The program is nationwide and automatic — Part D plans do not need to opt in. Before July 1, 2026, Medicare could cover Wegovy only for the cardiovascular risk-reduction indication in patients with established heart disease.
How much does Wegovy cost with insurance?
With commercial insurance that covers Wegovy plus the Wegovy Savings Offer (NovoCare copay card), most eligible patients pay as little as $25/month — up to $100/month in savings per fill, maximum 12 months. The savings card applies to both the injection and oral pill. Government insurance (Medicare, Medicaid, TRICARE, VA) cannot use the commercial copay card. Coverage varies by plan — as of 2026, over 41 million commercially insured Americans have no Wegovy coverage for weight loss, and over 88% of those who do have coverage face additional requirements like prior authorization.
How much does the Wegovy pill cost compared to the injection?
Both the Wegovy pill and injection carry the same $1,349/month list price. The difference appears in self-pay channels: via NovoCare Pharmacy, the pill starts at $149/month (starter 1.5 mg dose) versus $199/month for the injection starter dose. At maintenance doses, the pill runs $149–$299/month and the injection $199–$499/month. With commercial insurance and the savings card, both can be as low as $25/month. Under the Medicare GLP-1 Bridge, both are $50/month. The pill also avoids refrigeration and self-injection, which some patients prefer regardless of cost.
Is there a generic version of Wegovy available in the US?
No. As of 2026, there is no FDA-approved generic version of Wegovy in the United States. Semaglutide’s US patents are held by Novo Nordisk and are expected to begin expiring around 2031–2033. Compounded semaglutide from 503A pharmacies is legal under specific circumstances but is not an FDA-approved generic equivalent — it has not undergone the same safety and efficacy review as branded Wegovy. In countries like India and Canada, patent expiries are occurring in 2026, which may lower international prices, but US patients cannot legally import these versions for personal use.
Can I use GoodRx to get Wegovy cheaper?
GoodRx coupons reduce Wegovy’s retail price by roughly 10% — from $1,349 down to approximately $1,229 at Costco. This is still nearly $730 more per month than the NovoCare Pharmacy direct-pay option ($499). GoodRx and NovoCare direct cannot be stacked or combined. For most uninsured patients comparing cash-pay options, NovoCare direct ($199–$499/month) is a better choice than GoodRx retail unless you need same-day local pharmacy pickup.
Does Medicaid cover Wegovy?
Coverage depends on your state. As of January 2026, only 13 states provide Medicaid coverage for GLP-1 medications for obesity treatment — down from 16 in 2025, largely due to state budget pressure. If you have Medicaid and your state covers obesity GLP-1s, prior authorization is usually required. If your state does not cover Wegovy for weight loss, you may still qualify for the Novo Nordisk Patient Assistance Program based on income. Contact NovoCare at 1-888-693-4686 or visit needymeds.org to check current PAP eligibility regardless of Medicaid status.
Is compounded semaglutide safe and legal?
Compounded semaglutide is legal when prepared by a licensed 503A compounding pharmacy with a valid personalized prescription — for example, a dose strength not commercially available or a formulation with added ingredients. It is not FDA-approved, is not the same as branded Wegovy, and is not covered by insurance or the Medicare GLP-1 Bridge. The FDA has issued safety alerts about dosing errors and contamination risks with compounded injectable semaglutide. To verify a compounding pharmacy’s legitimacy, check NABP’s database at nabp.pharmacy. Telehealth platforms offering compounded semaglutide vary widely in quality — only use those that require a real clinical evaluation before prescribing.
What is the Wegovy patient assistance program and who qualifies?
Novo Nordisk’s Patient Assistance Program (PAP) may provide Wegovy at no cost to uninsured or underinsured patients who meet income eligibility requirements. Your prescriber must participate in the application process. To apply, visit novocare.com or call 1-888-693-4686. Income thresholds and eligibility criteria change periodically — confirm current requirements directly with Novo Nordisk. Independent resources such as NeedyMeds (needymeds.org) and RxAssist (rxassist.org) can also help you screen eligibility and identify additional assistance programs for weight-management medications.
How we reviewed this article:
SunnyPharma follows strict sourcing guidelines and relies on peer-reviewed studies, government agencies (FDA, CMS/Medicare, NIH, KFF), and manufacturer sources (NovoCare, Novo Nordisk). Cost and program details are drawn from official CMS program announcements, FDA safety communications, and published NovoCare pricing.
Read our editorial policy →Sources & References
- GoodRx Research. Tracking Insurance Coverage for Weight Loss Medications, 2026. goodrx.com
- Novo Nordisk. Wegovy Savings Offer Terms. NovoCare Pharmacy, 2026. novocare.com
- Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge Program Announcement. May 2026. cms.gov
- Novo Nordisk. Patient Assistance Program — NovoCare. 2026. novocare.com
- FDA. Approval of Oral Semaglutide (Wegovy Tablet) for Chronic Weight Management. December 2025. fda.gov
- FDA. Safety Communication: Dosing Errors with Compounded Injectable Semaglutide Products. 2025. fda.gov
- KFF. What to Know About the BALANCE Model and Medicare GLP-1 Bridge. May 2026. kff.org